Observational studyMedicina (Kaunas, Lithuania)2023

A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry.

Sabrina Kepka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.